Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593827 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT00593827: Completed Phase 2 study of Metastatic Breast Cancer, sponsored by R-Pharm.
NCT00593827 is a Phase 2 study of Metastatic Breast Cancer that has completed, run by R-Pharm. The registered enrollment target is 176 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00593827, a Phase 2 study of Metastatic Breast Cancer, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.
Primary Outcome
PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. Computed using Kaplan-Meier estimates.
Conditions Studied
Interventions
- DRUG Ixabepilone
Study Locations (20)
Arizona
- Hematology Oncology Associates - Phoenix
- Northern Arizona Hematology & Oncology Associates - Sedona
- Arizona Oncology Associates D.B.A. Hematology Oncology - Tucson
Florida
- Florida Cancer Institute - Hudson
- Ocala Oncology Center - Ocala
- Cancer Centers Of Florida, P.A - Ocoee
Missouri
- Missouri Cancer Associates - Columbia
- Kansas City Cancer Center, Llc - Kansas City
- Arch Medical Services, Inc. - St Louis
Indiana
- Central Indiana Cancer Centers - Carmel
- Hope Center - Terre Haute
Maryland
- Maryland Oncology Hematology, P.A. - Columbia
- Alliance Hematology Oncology, Pa - Westminster
Alabama
- Birmingham Hematology & Oncology Associates Llc - Birmingham
California
- Southwest Cancer Care - Murrieta
Illinois
- Cancer Care & Hematology Specialists Of Chicagoland - Niles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00593827 record still lists
NCT00593827 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ixabepilone is the first listed.
NCT00593827 names 20 study sites across 12 states, led by Arizona, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT00593827 about?
NCT00593827 is a clinical study titled "Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer". The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.
What is the current status of trial NCT00593827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2008-05. Estimated completion is 2010-08.
What conditions does trial NCT00593827 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00593827?
The interventions under investigation include: Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00593827?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00593827 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00593827's enrollment target sits among peer trials
176 36th of 139 higher than 103 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
- NCT04359069 · 176 participants · NA
Duration of Urinary Catheterization
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia